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The efficacy of tonsillectomy on long-term renal survival in Immunoglobulin A nephropathy (IgAN), which is char-
patients with IgA nephropathy. acterized by glomerular mesangial proliferation with a
Background. Little information has been available until now predominant IgA deposition in the mesangial areas, is theabout the clinical efficacy of tonsillectomy on long-term renal
most common glomerulonephritis worldwide, accountingsurvival of patients with idiopathic immunoglobulin A ne-
for 25% to 50% among primary glomerulonephritisphropathy (IgAN).
Methods. To investigate the effect of tonsillectomy on long- [1–3]. IgAN was initially considered a benign disease,
term renal survival, we reviewed the clinical course of 118 but long-term follow-up studies have shown the course
patients with idiopathic biopsy-diagnosed IgAN from 1973 to to be progressive with up to 50% of patients developing1980. Of those, 48 patients received tonsillectomy and 70 pa-
terminal renal failure after several decades [3–6]. Eventients did not. The starting point of observation was defined
IgAN with hematuria and minimal proteinuria is usuallyas the time of the diagnostic renal biopsy, and the end point
as when requiring the first dialysis. Up to 2001, the mean progressive and life-long follow-up with regular monitor-
observation time was 192.9  74.8 months (48–326 months). ing is recommended [7]. Since the pathogenesis of IgAN
Renal survival and impact of covariates were evaluated by is obscure, specific treatment is not yet available. Previ-Kaplan-Meier analysis and Cox proportional hazards regres-
ous approaches have included tonsillectomy, predniso-sion model.
lone, immunosuppressants, antihypertension drugs, anti-Results. Age, gender, amount of urinary protein excretion,
serum creatinine, serum IgA, blood pressure, and histopatho- coagulants, fish oils, and others [8–10].
logic findings at the time of renal biopsy and treatments during Although tonsillectomy has been expected to show
the observation period were not significantly different between efficacy, up to now there has been little informationpatients with and without tonsillectomy. Five (10.4%) of the
about the clinical effect of tonsillectomy on long-termpatients with tonsillectomy and 18 (25.7%) of the patients
renal survival in which the mean observation time ex-without tonsillectomy finally required dialysis therapy (chi-
square test, P  0.0393). By Kaplan-Meier analysis, renal sur- ceeded 10 years in patients with IgAN. Previous studies
vival rates were 89.6% and 63.7% at 240 months in the patients demonstrated that half of the patients with IgAN showed
with and without tonsillectomy, respectively, and were signifi- distinct improvement in urinary findings or/and the levels
cantly different (log-rank test, P 0.0329). In the multivariate
of serum IgA, the circulating immune complex and se-Cox regression model, tonsillectomy (hazard ratio, 0.22; 95%
rum polymeric IgA, several months or several years afterCI, 0.06 to 0.76; P  0.0164) had a significant effect on renal
outcome. tonsillectomy [11–13]. Recently, Hotta et al [14] used
Conclusion. These results indicate that tonsillectomy has a Cox proportional hazards model and reported that a
favorable effect on long-term renal survival in patients with combination of tonsillectomy and steroid pulse therapy
IgAN.
had a significant impact on clinical remission, defined as
negative proteinuria and hematuria, in IgAN patients
with a median follow-up duration of 75 months, but theKey words: tonsillectomy, immunoglobulin A nephropathy, renal sur-
vival. impact of tonsillectomy on long-term renal survival was
unclear. In addition, the clinical benefit of tonsillectomyReceived for publication August 12, 2002
in patients with IgAN remains controversial. Rasche,and in revised form November 1, 2002
Accepted for publication January 3, 2003 Schwarz, and Keller [15] estimated the probability of
renal survival 10 years after renal biopsy and the impact 2003 by the International Society of Nephrology
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of risk factors in patients with IgAN by Kaplan-Meier pressure and diastolic pressure, degree of proteinuria
and hematuria, serum creatinine and serum IgA level.analysis and Cox regression model. The results were not
significantly different between 16 patients with tonsillec- If the amount of urine protein excretion was less than
0.1 g/24 hours, it was considered to be 0.1 g/24 hours.tomy and 39 patients without tonsillectomy. Their mean
observation time after renal biopsy was relatively short The numbers of urine red blood cells with macrohematu-
ria were defined as 100/high power field when calculating.(3.4  4 years) in that study.
To clearly establish the effect of tonsillectomy on long- The histologic score was from primary pathologic diag-
nostic reports using light microcopy. The severity of glo-term renal survival, we compared the clinical course of
IgAN patients with and without tonsillectomy in which merular mesangial proliferation, global glomerular scle-
rosis, interstitial lesions, and crescent formation in eachthe mean observation time was over 15 years, and esti-
mated renal survival and the impact of multiple covari- case was graded semiquantitatively from 0 to 4, according
to the percentage of injured tissue, respectively. Theates, including clinical and pathologic findings, on the
prognosis by Kaplan-Meier analysis and Cox regression grades were as follows: 0  no lesion (or interstitial
lesions were less than 5%); 125% (interstitial lesionmodel. The results showed that tonsillectomy had a fa-
vorable effect on long-term renal survival in patients was defined as5% and25%); 225% and50%;
3  50% and 75%; and 4  75%.with IgAN.
Tonsillectomy and drug therapy
METHODS
Almost all IgAN patients had their tonsils checked and
Patients underwent bacterial culture by otolaryngologists during
hospitalization in a clinical nephrology division, evenAmong 555 patients who underwent renal biopsy and
immunofluorenscence examination between 1973 and those without tonsillectomy. The indication for tonsillec-
tomy in patients with IgAN was chronic tonsillitis or a1980, we identified 162 inpatients with IgAN followed-up
at our department. The diagnosis was limited to primary positive tonsil provocation test estimated by otolaryn-
gologists. Chronic tonsillitis included chronic hypertro-glomerulonephritis with a predominant deposition of
IgA in the mesangium. No patients had clinical or histo- phic tonsillitis and chronic atrophic tonsillitis. The latter
was the prevalent form in adult chronic tonsillitis andlogic evidence of systemic diseases as systemic lupus
erythematosus, Henoch-Scho¨nlein purpura, or chronic mainly revealed cryptic large tonsils with inflammatory
debris or fibrotic tonsils because of recurrent infectionliver disease. Exclusion criteria for the present study
were a follow-up period less than 48 months. As a result, and scarring. Adoption of tonsillectomy arbitrarily de-
pended on the will of each patient or the recommenda-118 of the 162 patients with IgAN were included in this
study. Forty-eight patients underwent tonsillectomy, and tion of physicians after examination by otolaryngologists.
Tonsillectomy was performed before, during, or after70 patients did not, before or after renal biopsy.
hospitalization for a diagnostic renal biopsy.
Follow-up and outcome measures Drug therapies included steroid (prednisolone), im-
munosuppressant (cyclophosphamide or azathioprine),At the time of the annual birthday of every patient
after renal biopsy, letters were sent to each one inviting antiplatelet or anticoagulant (dipyridamole or warfarin),
and antihypertension [diuretics,  blockers,  blockers,them to our hospital or affiliated hospitals for examina-
tions of blood pressure, urinalysis, and renal function. calciumantagonists,angiotensin-convertingenzyme (ACE)
inhibitors and others] therapies during follow-up. DataThen, we stored the results of the examinations or cur-
rent physical status and treatment (living or dead, requir- regarding the treatments were recorded from primary
medical records and the outcomes of follow-up, such asing dialysis or not, and any treatment or not) in a com-
puter data bank. outclinic records and questionnaires. Most patients were
not given any drugs during follow-up according to theThe starting point of observation in this study was
defined as the time of the diagnostic renal biopsy, and policy two decades ago.
the end point as the time when the first dialysis was
Statistical analysisrequired. All patients in this study were followed up for
more than 48 months. Renal survival was defined as We used the chi-square test to analyze the frequency
of categorical variables. Differences in the continuousdialysis-free.
variables between the groups were compared using the
Clinical, laboratory, and pathologic data Mann-Whitney U test (Wilcoxon rank sum test) and the
unpaired t test (Student t test). As the results were simi-Baseline clinical and laboratory data at the time of
the diagnostic renal biopsy were chosen from primary lar, only the latter are presented. The renal survival
curves and cumulative renal survival rates for IgAN pa-case records. Patient characteristics included age, gen-
der, and mean arterial pressure calculated from systolic tients in the groups were calculated using the Kaplan-
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Table 1. Baseline characteristics of the patients with immunoglobulin A nephropathy (IgAN)
Tonsillectomy Non-tonsillectomy
Characteristic N  48 N  70 P value
At the time of biopsy
Male/female 28/20 36/34 NS
Age years 30.3511.46 33.6412.03 NS
Mean arterial pressure mm Hg 97.3912.66 96.7112.64 NS
Urine red blood cells /high power field 39.5343.00 44.5842.77 NS
Urine protein g/24 hours 0.911.12 1.091.43 NS
Serum creatinine mg/dL 1.070.27 1.070.31 NS
Serum IgA mg/dL 375.7131.0 363.9125.4 NS
Chronic tonsillitis  31 41 NS
Pathologic finding
Mesangial proliferation 2.730.73 2.470.92 NS
Global glomerular sclerosis 0.770.94 0.901.00 NS
Interstitial lesion 0.770.77 0.890.96 NS
Crescent formation 0.460.66 0.340.60 NS
Background therapy
Antihypertension 14 14 NS
Steroid 4 13 NS
Immunosuppressant 4 13 NS
Antiplatelet 5 15 NS
No drugs 27 32 NS
NS is not significant. Data  meanSD. The damage severity of renal biopsy tissue was graded from 0 to 4 according to the percentage of the lesion range,
respectively. 0  No lesion (or interstitial lesions were 5%); 1  25% (interstitial lesion was defined as 5% and 25%); 2  25% and 50%; 3  50%
and 75%; and 4  75%. Antihypertension drugs included diuretics,  blockers,  blockers, calcium antagonists, angiotensin-converting enzyme inhibitors and
others. Steroids included prednisolone. Immunosuppressants included cyclophosphamide or azathioprine. Antiplatelets included dipyridamole or warfarin.
Meier analysis. Comparisons of the time course from 70.0 months, respectively. The amount of urine protein
excretion in 45 (38.1%) of 118 patients was less than 0.5renal biopsy to end points between the groups were
performed by means of a log-rank test. To estimate the g/24 hours. Thirty-nine (33.1%) patients presented with
macrohematuria at the time of renal biopsy. Baselinesize of the effect, we used a Cox regression model, choos-
ing a forward stepwise procedure to assess the impact clinical and laboratory data at the time of renal biopsy
were not statistically different between the tonsillectomyof multiple covariates for renal prognosis. Variables used
in multivariable analysis were expressed using a binary and nontonsillectomy groups (Table 1).
The damage severity of renal biopsy tissue, includingscale, such as absent/present, and coded as 0/1. Mean
arterial pressure, amount of urine protein excretion, se- glomerulus, interstitium, and vessels, was examined with
light microscopy and was evaluated semiquantitatively.rum creatinine level, global glomerular sclerosis, inter-
stitial lesions, crescent formation, steroid therapy, and The comparison of renal biopsy pathologic findings be-
tween the tonsillectomy and nontonsillectomy groupstonsillectomy were treated as categoric variables. The
results of multivariable analysis were expressed by a was not statistically different (Table 1). Arterial sclerosis
and adhesion were not statistically different either (datahazard ratio and 95% confidence intervals. In the Cox
analysis, exp () was the hazard ratio for a case with not shown).
The medical therapies included steroid, immuno-the characteristic, as compared to a case without the
characteristic. For all analyses, P  0.05 was considered suppressive, antiplatelet, and antihypertensive agents.
Twenty-seven patients with tonsillectomy and 32 patientsstatistically significant. StatView 5.0 statistical software
(Abacus Concepts, Inc., Berkeley, CA, USA) was used without tonsillectomy did not undergo any drug therapy
during follow-up. The treatments in the tonsillectomyfor statistical analysis.
and nontonsillectomy groups were not significantly dif-
ferent (Table 1).
RESULTS
Baseline characteristics Clinical outcomes
One (2.1%) of the tonsillectomy patients and twoForty-eight patients underwent tonsillectomy and 70
patients did not before or after renal biopsy. The mean (2.9%) of the nontonsillectomy patients died due to an
accident, bacterial infection, and cerebral hemorrhage,duration of follow-up for the 118 IgAN patients with and
without tonsillectomy was 192.9 74.8 months (median, respectively, before renal failure. The mortality in the
tonsillectomy and nontonsillectomy groups was not sig-189.5 months; range, 48 to 326 months). The mean fol-
low-up periods in the tonsillectomy and nontonsillec- nificantly different (Fig. 1).
Five (10.4%) of 48 patients with tonsillectomy reachedtomy groups were 210.2  78.9 months and 180.1 
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Fig. 1. Comparison of mortality before renal failure and incidence of
dialysis event in the tonsillectomy and nontonsillectomy groups.
Fig. 3. Hazard ratios for the Cox regression model in immunoglogulin
A nephropathy (IgAN). Numbers are hazard ratios with 95% confidence
intervals (0.95% CI). Global glomerular sclerosis, crescent formation,
a large amount of urine protein excretion, and elevated serum creatinine
were statistically significant risk factors for renal prognosis. Conversely,
tonsillectomy showed a favorable effect on renal prognosis. Abbrevia-
tions are: MAP, mean arterial pressure; UP, urine protein excretion.
Fig. 2. Kaplan-Meier analysis of renal survival (dialysis-free) in immu-
noglobulin A nephropathy (IgAN) patients with () and without ()
tonsillectomy. The rates of renal survival in IgAN patients with and pact factors for renal prognosis) revealed that global
without tonsillectomy were 97.6%, 89.6%, 89.6%, 83.2%, and 88.8%,
glomerular sclerosis, crescent formation, a high amount74.0%, 63.7%, and 63.7% 120, 180, 240, and 300 months after renal
biopsy, respectively. of urine protein excretion, and elevated serum creatinine
to be statistically significant risk factors for renal progno-
sis. Conversely, tonsillectomy was found to have a favor-
able effect on renal prognosis (Fig. 3).the end point and required dialysis therapy, whereas 18
(25.7%) of 70 patients without tonsillectomy required
Comparison of tonsillectomy patients requiring or notdialysis therapy. Between the two groups there was a
requiring dialysissignificant difference (	2  4.246, P  0.0393) (Fig. 1).
In order to further understand the renal indication and
Renal survival in patients with and efficiency or limitations of tonsillectomy, we compared
without tonsillectomy the baseline characteristics and histopathologic findings
of 48 tonsillectomy IgAN patients with and without dial-The mean renal survival time and cumulative renal
ysis. As a result, the amount of urinary protein excretionsurvival rate were evaluated by Kaplan-Meier analysis.
at the time of renal biopsy and grades of global glomeru-The mean renal survival time was 243.8 months (standard
lar sclerosis and crescent formation in five patients re-error 7.0), and the cumulative renal survival rates were
quiring dialysis were significantly higher than those in97.6%, 89.6%, 89.6%, and 83.2% at 120, 180, 240, and
43 patients not requiring dialysis (2.04  2.24 g/24 hours300 months, respectively, in the patients with tonsillec-
vs. 0.77  0.86 g/24 hours, P  0.0155; 1.60  1.52 vs.tomy. In the patients without tonsillectomy, the mean
0.67  0.81, P  0.0343; and 1.40  0.89 vs. 0.33  0.53,renal survival time was 213.7 months (standard error
P  0.0003, respectively) (Fig. 4).6.6), and the cumulative renal survival rates were 88.8%,
74.0%, 63.7%, and 63.7% at the 120, 180, 240, and 300
Comparison of tonsillectomy efficacy undermonths, respectively. In the log-rank test, there was a
different conditionssignificant difference between the two groups (P 
With a mild renal injury condition, where the amount0.0329) (Fig. 2).
of urine protein excretion was less than 1.0 g/24 hours
Cox regression analysis and global glomerular sclerosis less than 25%, none of
26 patients with tonsillectomy needed dialysis, whereasMultivariate Cox regression analysis with the eight
most important clinicopathologic variables (potential im- five (13.2%) of 38 patients without tonsillectomy re-
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4 years after tonsillectomy. Remission of proteinuria was
observed in 41.7% of patients 6 months after tonsillec-
tomy and in 50.0% 2 years after the surgery [13]. The
clinical remission rate and stable renal function rate in
IgAN patients with tonsillectomy were significantly
higher than those in nontonsillectomy patients [19].
Hotta et al [14] conducted a retrospective investigation
of the renal outcome in IgAN patients with a median
observation period of 75 months after tonsillectomy and
steroid pulse therapy. Their results showed that there
were no significant differences between the tonsillectomyFig. 4. Comparison of main baseline characteristics in tonsillectomy
patients requiring or not requiring dialysis. The grades of global glomer- and nontonsillectomy groups regarding the incidence of
ular sclerosis and crescent formation were defined as 0  no lesion; progressive renal functional loss, defined as a 50% in-1  25% of the lesion range; 2  25% and 50%, respectively.
crease in baseline serum creatinine, but a combination of
tonsillectomy and steroid pulse therapy had a significant
impact on clinical remission by multivariate Cox regres-
sion analysis. Forty-eight percent of patients achievedquired dialysis. The percent requiring dialysis in the ton-
clinical remission (disappearance of urinary abnormali-sillectomy patients with moderate renal injury was less
ties) and none of these remission patients revealed athan half of that in the nontonsillectomy patients, al-
progressive deterioration in renal function, defined as athough there was no statistical difference between the
50% increase in the serum creatinine level from thetwo groups. On the other hand, in the patients with
baseline [14]. Thirty-five patients with IgAN, in whommarked renal injury, tonsillectomy had no distinct effect
hematuria had disappeared after a treatment protocolon renal outcome (Table 2).
involving high doses of methylprednisolone and tonsil-
lectomy, underwent a repeat biopsy; mesangial prolifera-
DISCUSSION tion and acute inflammatory glomerular lesions, renal
In the present study, we investigated the impact of interstitial injury, and IgA mesangial deposits were sig-
tonsillectomy on long-term renal survival in patients with nificantly reduced in second-biopsy specimens [20]. In
IgAN. There were two characteristics in this study. First, the present study, we used three different statistical
to our knowledge, the present study had the longest methods including the chi-square test, Kaplan-Meier
follow-up time, with a mean follow-up duration of more method with log-rank test, and Cox regression propor-
than 15 years (192.9  74.8 months) on the efficacy of tional hazards model in order to establish the efficacy
tonsillectomy in IgAN patients. Second, the end point of of tonsillectomy in IgAN patients. A mean 15 years after
the observation in this study was from the time requiring a diagnostic biopsy, only five (10.4%) of 48 tonsillectomy
dialysis, that is, renal death, not the time of a 50% in- patients entered dialysis, whereas 18 (25.7%) of 70 non-
crease in baseline serum creatinine. Although the end tonsillectomy patients required dialysis, by chi-square
point of observation in the study by Rasche, Schwarz, test, P 0.0393. Kaplan-Meier analysis showed the renal
and Keller [15] was also end-stage renal failure, the mean survival rates of tonsillectomy patients were statistically
observation time after renal biopsy was only 3.4  4 higher than those of nontonsillectomy ones 10, 15, 20,
years. It is difficult to assess the real prognosis of patients and 25 years after renal biopsy, respectively (log-rank
with IgAN with a short observation time of less than 5 test, P  0.0329). Cox regression analysis showed that
years, because only a small proportion of them enter the relative risk for terminal renal failure in patients with
dialysis treatment within 5 years [3, 16, 17]. tonsillectomy was lower compared to nontonsillectomy
Regarding the impact of tonsillectomy on progression patients (P  0.0164). The results of these three statisti-
and prognosis of IgAN, previous studies have demon- cal analyses were consistent: all revealed that tonsillec-
strated that tonsillectomy improves immunologic abnor- tomy had a favorable effect on long-term renal survival
malities, urinary abnormalities, renal function, and renal in patients with IgAN.
histopathologic findings in patients with IgAN (detailed Although the mechanism regarding the favorable ef-
in the next section). This study showed that tonsillectomy fect of tonsillectomy on renal survival in IgAN patients
was an independent favorable factor on long-term renal is still unclear, previous studies have suggested that the
survival in patients with IgAN. tonsils are closely related to IgAN. IgAN is initiated by
Bene et al [18] reported that the serum IgA level glomerular deposition of polymeric IgA1. Tomino et al
and amount of urinary protein excretion significantly [21] demonstrated that the antibodies eluted from renal
decreased, while serum creatinine concentration was sta- tissues of IgAN specifically bound with the nuclear re-
gions of tonsillar cells. The binding of eluted antibodiesble, in patients with IgAN from 6 months to more than
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Table 2. Comparison of tonsillectomy efficacy under different conditions
Tonsillectomy Nontonsillectomy
Mild renal injury
Urine protein 1 g/24 hours and global glomerular sclerosis grade 
1 0/26 (0.0%) 5/38 (13.2%)
Moderate renal injury
Urine protein 1 g/24 hours 4/16 (25.0%) 12/22 (54.5%)
Global glomerular sclerosis grade 2 2/6 (33.3%) 9/13 (69.2%)
Crescent formation grade 1 4/16 (25.0%) 9/17 (52.9%)
Marked renal injury
Urine protein 1 g/24 hours and global glomerular sclerosis grade 2 1/2 (50.0%) 8/10 (80.0%)
Urine protein 1 g/24 hours and crescent formation grade 1 3/7 (42.9%) 5/9 (55.6%)
Crescent formation grade 2 3/4 (75.0%) 4/4 (100.0%)
Numbers refer to numbers of patients requiring dialysis. Although there was no statistical difference between the two groups, the percentage entering dialysis in
the tonsillectomy patients with mild or moderate renal injury was less than half of that in the nontonsillectomy patients. Renal tissue injury grade 
1 includes 0 and
1; grade 1  1% and 25%, grade 2  25% and 50%.
and tonsillar cells was completely inhibited by the addi- formed. Tonsillectomy was mainly indicated for patients
with mild IgAN, in which the amount of urine proteintion of antihuman IgA antisera [21]. In tonsils without
IgAN, the predominance of IgG-secreting cells was ob- excretion was less than 1.0 g/24 hours and global glomer-
ular sclerosis was less than 25%.served, while in IgAN patients, abnormal numbers of
IgA-producing cells could be found in the tonsillar tissue, Although this study was performed in a retrospective
style, we believe the clinical and histologic data of theresulting in an inverted IgG/IgA ratio. Moreover, most
IgA-producing cells were polymeric IgA-secreting cells baseline and the outcomes of end points are precise,
because follow-up after renal biopsy was done annually(J chain-positive) [22–25]. A further study showed that
the IgA1 subclass was demonstrated in follicular den- with accurate records. The long observation periods en-
dritic cells of the tonsils in IgAN patients, but not in the abled us to obtain results showing a significant difference
cells of non-IgAN controls [26]. A greater number of J in the incidence of renal death over 15 years after tonsil-
chain mRNA-positive cells were found in the tonsillar lectomy. Although randomized prospective controlled
germinal centers of IgAN patients compared with con- trials are very important, a randomized control study
trols [27]. These results indicate that the polymeric IgA1 of a surgical operation such as tonsillectomy is hard to
deposited in the mesangium may be at least in part of perform, and long-term follow up more than 10 years
tonsillar origin. In addition, recurrent tonsillitis appears is not easy. Therefore, even if the bias as a result of
as the most frequent extrarenal clinical manifestation retrospective study is taken into account, we believe this
occurring in IgAN [28], and there are close time relation- study will have referential value for clinicians. Unfortu-
ships between pharyngeal infectious episodes and bouts nately, we could not accurately measure drug dosage or
of hematuria and/or proteinuria [18]. Suzuki et al [29] continual time of medical therapies during the clinical
reported that the antigens and antibodies of outer mem- course in this study. Although we have detailed therapy
branes of Haemophilus parainfluenzae, a common bacte- protocols on IgAN at present, there were no detailed
rium on the tonsils, were present in the glomerular mes- treatment plans two decades ago. Only a small fraction
angium and sera of IgAN, respectively [29]. Tonsillar of patients underwent medical therapy in this study. One
lymphocytes from patients with IgAN had a significantly possible explanation is that the prognosis of IgAN was
higher stimulation index on exposure to H. parainfluen- initially considered to be favorable [31]. According to
zae antigens and a significantly higher IgA stimulation the policy two decades ago, many patients with mild
index than did controls [30]. Tonsillectomy could thus IgAN were not given any agents after diagnosis.
lead to the disappearance of lymphoid tissue actively
recruiting activated IgA-producing cells and the removal
CONCLUSIONof a pharyngeal infectious focus, and explain partly the
The results of this study showed tonsillectomy had adecrease in serum IgA level and mesangial IgA deposits,
favorable effect on long-term renal survival in patientsand subsequent remission in IgAN.
with IgAN. Since no specific method has been availableRegarding the limitations and indication of tonsillec-
for the treatment of IgAN, tonsillectomy could be usedtomy in patients with IgAN, our data (Fig. 4 and Table
as a potentially effective treatment, especially in patients2) suggested that when the amount of urine protein ex-
with mild IgAN. However, tonsillectomy may not becretion was more than 1.0 g/24 hours and global glomeru-
enough, because of multiple related factors in the pro-lar sclerosis was greater than 25%, or crescent formation
gression in patients with IgAN, including genetic factorswas greater than 25%, patients could develop renal fail-
ure requiring dialysis even if tonsillectomy was per- [32–35]. In IgAN patients with marked renal injury, ton-
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vent a progressive course in IgA nephropathy. Clin Nephrolsillectomy may not affect the prognosis of IgAN. In order
51:147–152, 1999
to further clarify the clinical efficacy of tonsillectomy, 16. Bailey RR, Lynn KL, Robson RA, et al: Long term follow up of
patients with IgA nephropathy. N Z Med J 107:142–144, 1994randomized prospective controlled trials are necessary.
17. Wyatt RJ, Kritchevsky SB, Woodford SY, et al: IgA nephropa-
thy: Long-term prognosis for pediatric patients. J Pediatr 127:913–
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